5
21
3
↑5
↓21
—3
Evidence suggests Psilocybin maydecreaseAnxiety.
26 studies (29 claims)
Moderate consensus
Typical effective dose 4.7 (1.85–20) mgacross 6 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Psilocybin therapy | Decreases - consistently showed significant reductions in | anxiety | Human | cancer patients | Not specified in the abstract. | Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. |
| psilocybin therapy | Decreases - improved to a clinically meaningful degree | Hamilton Anxiety Rating Scale (HAM-A) scores | Human | people with mild to moderate stage PD plus depression and/or anxiety | One 10 mg dose followed by one 25 mg dose, administered with psychotherapy. | Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. |
| Oral psilocybin | Decreases - producing statistically significant reductions | depression and anxiety symptoms | Human | multiple clinical trials | Not mentioned | The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.cited 19× |
| psychotherapy-assisted psilocybin applications | Decreases - opened new avenues in the treatment | life-threatening cancer-related anxiety and depression | Human | patients with life-threatening cancer | Not specified | Psychedelic therapy in depression and substance use disorders.cited 10× |
| Psilocybin and LSD | Decreases - reduced anxiety and depression | anxiety and depression | Human | cancer patients | Not specified | Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.cited 131× |
| hallucinogens like lysergic acid diethylamide and psilocybin | Decreases - inducing substantial perceptual and cognitive shifts that facilitate deep psychological introspection and significant therapeutic advances | depression and anxiety disorders | Human | patients suffering from depression and anxiety disorders | Not specified | Psychoactive substances for the treatment of neuropsychiatric disorders.cited 2× |
| a single 25 mg oral dose of psilocybin | No effect - No significant differences were found | anxiety | Human | medication discontinued versus unmedicated at screening groups | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| psilocybin-assisted psychotherapy | Increases - Comparable improvements were observed | depression and anxiety and symptoms | Human | antidepressant discontinued and UAS patients | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| ayahuasca, psilocybin and lysergic acid diethylamide (LSD) | Decreases - may have antidepressive, anxiolytic, and antiaddictive properties | mood and anxiety disorders and drug dependence | Human | patients | Not specified | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.cited 163× |
| ayahuasca, psilocybin and LSD | Decreases - suggest beneficial effects | anxiety and depression associated with life-threatening diseases | Human | patients | Not specified | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.cited 163× |
| ayahuasca, psilocybin and LSD | Decreases - may be useful pharmacological tools for the treatment | drug dependence, and anxiety and mood disorders | Human | treatment-resistant patients | Not specified | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.cited 163× |
| ketamine, psilocybin and cannabidiol | Decreases - are in the process of gathering evidence in support of the treatment | anxiety disorders | Human | — | Not specified | Update on treatments for anxiety-related disorders.cited 15× |
| psilocybin-assisted psychotherapy | Increases - most common adverse events during and after sessions included | anxiety | Human | clinical populations | Heterogeneous doses (specific amounts not detailed in the abstract). | The safety of psilocybin-assisted psychotherapy: A systematic review.cited 1× |
| psilocybin | Decreases - highly promising preliminary data have been produced | anxiety | Human | — | Not specified | Psychedelic drugs-a new era in psychiatry? .cited 53× |
| psilocybin | Decreases - showed a significant improvement | anxiety | Animal | SAPAP3 KO mice | 4.4 mg/kg, single intraperitoneal injection. | Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming.cited 6× |
| psilocybin | Decreases - supports its efficacy | anxiety | Human | — | Not specified | The Emergence of Psilocybin in Psychiatry and Neuroscience. |
| psilocybin | Decreases - reduction | anxiety | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.cited 59× |
| psilocybin | Decreases - has shown great potential for treatment | anxiety and depression | Human | — | Not specified | Sustained effects of single doses of classical psychedelics in humans.cited 28× |
| psilocybin | Decreases - induced anxiolytic-like | anxiety-like behaviors | Animal | mice | 5 mg/kg (intraperitoneal) | Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner.cited 1× |
| psilocybin | No effect - did not have any effect on | anxiety-like behaviours | Animal | male and female SAPAP3 knockout (KO) mice | 1 mg/kg, intraperitoneal (single dose). | Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour.cited 1× |
| psilocybin (1 mg/kg) | No effect - did not alter | anxiety-like behaviours | Animal | both genotypes | 1 mg/kg (single dose). | Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.cited 1× |
| psilocybin | Increases - was significantly more effective | anxiety symptoms | Human | patients with MDD | Not specified in the abstract. | Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.cited 3× |
| psilocybin | Decreases - reduced | anxiety symptoms | Human | patients with MDD | Not specified in the abstract. | Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.cited 3× |
| psilocybin | No effect - support the efficacy | cancer-related anxiety | Human | — | Not available. | Psychedelics and Psychedelic-Assisted Psychotherapy.cited 315× |
| psilocybin | Increases - has been shown to predict favourable changes in | patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use | Human | patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use | Not specified | Psychedelics and health behaviour change.cited 41× |
| psilocybin | Decreases - can manage | substance use disorders and end-of-life anxiety | Human | — | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |
| psilocybin | Decreases - evidence was also found for the efficacy | symptoms of anxiety | Human | patients with life-threatening somatic illnesses, such as cancer | Not specified | Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. |
| psilocybin | Decreases - produced immediate and significant anti-depressant and anxiolytic effects | symptoms of depression and anxiety | Human | patients with depression and/or anxiety | Not specified | Classical psychedelics for the treatment of depression and anxiety: A systematic review.cited 123× |
| A single high dose of psilocybin in combination with therapy | Decreases - was found to lower | symptoms of anxiety | Human | participants | Single high dose (exact amount not specified). | Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. |